Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
1.83% $2.23
America/New_York / 20 sep 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 127.83 mill |
EPS: | -1.110 |
P/E: | -2.01 |
Earnings Date: | Oct 31, 2023 |
SharesOutstanding: | 57.32 mill |
Avg Daily Volume: | 0.600 mill |
RATING 2023-09-29 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.01 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.34x |
Company: PE -2.01 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.21 - 2.26 ( +/- 1.12%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-21 | Baylor-henry Minnie | Sell | 32 800 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 26 400 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 12 800 | Stock option (right to buy) |
2023-09-21 | Hoffmann Rolf K | Sell | 64 000 | Common Stock |
2023-09-21 | Hoffmann Rolf K | Sell | 20 000 | Common Stock |
INSIDER POWER |
---|
-63.68 |
Last 96 transactions |
Buy: 1 606 755 | Sell: 5 363 965 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.23 (1.83% ) |
Volume | 4.48 mill |
Avg. Vol. | 0.600 mill |
% of Avg. Vol | 746.42 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.